Raymond James Trust N.A. Purchases 2,163 Shares of CME Group Inc. (NASDAQ:CME)

Raymond James Trust N.A. increased its position in CME Group Inc. (NASDAQ:CME) by 5.9% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 38,530 shares of the financial services provider’s stock after purchasing an additional 2,163 shares during the quarter. Raymond James Trust N.A.’s holdings in CME Group were worth $7,575,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Gold Investment Management Ltd. purchased a new stake in CME Group during the fourth quarter worth $26,000. Salomon & Ludwin LLC purchased a new stake in shares of CME Group during the 1st quarter valued at $28,000. Northwest Financial Advisors purchased a new stake in shares of CME Group during the 4th quarter valued at $28,000. Rise Advisors LLC purchased a new position in CME Group in the 1st quarter worth $41,000. Finally, McClarren Financial Advisors Inc. raised its stake in CME Group by 89.5% in the 1st quarter. McClarren Financial Advisors Inc. now owns 216 shares of the financial services provider’s stock worth $47,000 after acquiring an additional 102 shares during the last quarter. Hedge funds and other institutional investors own 87.75% of the company’s stock.

Insider Activity

In other news, Director Charles P. Carey sold 3,000 shares of the firm’s stock in a transaction dated Thursday, June 13th. The stock was sold at an average price of $195.44, for a total transaction of $586,320.00. Following the sale, the director now directly owns 7,163 shares in the company, valued at approximately $1,399,936.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Daniel R. Glickman sold 650 shares of CME Group stock in a transaction that occurred on Thursday, June 6th. The stock was sold at an average price of $201.44, for a total value of $130,936.00. Following the sale, the director now directly owns 14,008 shares of the company’s stock, valued at $2,821,771.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Charles P. Carey sold 3,000 shares of the stock in a transaction on Thursday, June 13th. The shares were sold at an average price of $195.44, for a total value of $586,320.00. Following the completion of the transaction, the director now directly owns 7,163 shares of the company’s stock, valued at $1,399,936.72. The disclosure for this sale can be found here. Insiders own 0.30% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. JPMorgan Chase & Co. raised their target price on CME Group from $187.00 to $191.00 and gave the stock an “underweight” rating in a research note on Thursday, July 25th. Barclays raised their target price on CME Group from $208.00 to $209.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 25th. Deutsche Bank Aktiengesellschaft raised their target price on CME Group from $193.00 to $200.00 and gave the stock a “hold” rating in a research note on Thursday, August 15th. Piper Sandler restated an “overweight” rating and issued a $225.00 target price on shares of CME Group in a research note on Tuesday, August 20th. Finally, Keefe, Bruyette & Woods raised their target price on CME Group from $212.00 to $213.00 and gave the stock a “market perform” rating in a research note on Thursday, July 25th. Three analysts have rated the stock with a sell rating, six have issued a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, CME Group has an average rating of “Hold” and a consensus target price of $213.27.

CME Group Stock Performance

CME traded down $2.57 during midday trading on Friday, hitting $207.05. 1,273,912 shares of the company were exchanged, compared to its average volume of 1,924,431. The company’s 50 day simple moving average is $199.69 and its 200 day simple moving average is $207.19. The firm has a market capitalization of $74.55 billion, a price-to-earnings ratio of 23.56, a price-to-earnings-growth ratio of 6.27 and a beta of 0.52. The company has a current ratio of 1.02, a quick ratio of 1.01 and a debt-to-equity ratio of 0.10. CME Group Inc. has a 1-year low of $190.70 and a 1-year high of $223.80.

CME Group (NASDAQ:CME) last posted its earnings results on Wednesday, July 24th. The financial services provider reported $2.56 EPS for the quarter, beating analysts’ consensus estimates of $2.53 by $0.03. CME Group had a return on equity of 12.82% and a net margin of 56.98%. The firm had revenue of $1.53 billion for the quarter, compared to analysts’ expectations of $1.53 billion. During the same period last year, the firm earned $2.30 EPS. The company’s quarterly revenue was up 12.7% on a year-over-year basis. As a group, sell-side analysts predict that CME Group Inc. will post 9.8 earnings per share for the current year.

CME Group Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 25th. Stockholders of record on Monday, September 9th will be given a dividend of $1.15 per share. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.22%. The ex-dividend date of this dividend is Monday, September 9th. CME Group’s dividend payout ratio (DPR) is presently 52.33%.

CME Group Profile

CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.